BlackBarn Capital Partners LP Buys 543,029 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BlackBarn Capital Partners LP boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 107.1% in the fourth quarter, HoldingsChannel reports. The firm owned 1,050,000 shares of the company’s stock after purchasing an additional 543,029 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 1.3% of BlackBarn Capital Partners LP’s holdings, making the stock its 4th largest holding. BlackBarn Capital Partners LP’s holdings in Teva Pharmaceutical Industries were worth $23,142,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after buying an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Lingotto Investment Management LLP raised its stake in shares of Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after purchasing an additional 688,862 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after buying an additional 569,412 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company’s stock worth $203,642,000 after buying an additional 489,041 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Monday, April 14th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Finally, UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $13.30 on Tuesday. The company’s fifty day moving average is $15.39 and its two-hundred day moving average is $17.65. The company has a market cap of $15.08 billion, a P/E ratio of -9.17, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.